Pharma giant Roche pledges $50 billion US investment in R&D, manufacturing
Swiss pharmaceutical giant Roche unveiled ambitious plans on Tuesday for a substantial $50 billion investment in the United States over...
Swiss pharmaceutical giant Roche unveiled ambitious plans on Tuesday for a substantial $50 billion investment in the United States over...
Income-focused exchange-traded funds have retreated this year, mirroring the performance of mainstream Wall Street indices like the Nasdaq 100 and...
Shares of metal companies rose up to 2% on Monday, tracking gains in broader markets, after the Indian government imposed...
European financial markets returned from the extended Easter weekend to a climate of apprehension on Tuesday, opening lower as simmering...
The ZIM stock price has remained in a technical bear market, declining by over 37% from its peak in December....
Gold price has continued to surge this year, becoming the best-performing major asset. It has soared by almost 30% and...
Netflix executives messaged Thursday that all is well with the business in the face of economic turbulence. But its full-year outlook...
The S&P 500 index has suffered a harsh reversal this year as it crashed by 14% from its highest point...
The Dow Jones Index has entered a correction this year, having dropped by over 13% from its highest level. The...
Brent crude oil price has stabilized a bit in the past two weeks as concerns about demand and supply remains....
Disclaimer: EarningsMastery.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.